ValuEngine Upgrades Emergent Biosolutions (NYSE:EBS) to “Hold”

ValuEngine upgraded shares of Emergent Biosolutions (NYSE:EBS) from a sell rating to a hold rating in a report issued on Friday, March 29th, ValuEngine reports.

EBS has been the subject of a number of other reports. Cantor Fitzgerald set a $75.00 price objective on Emergent Biosolutions and gave the company a buy rating in a research note on Thursday, December 13th. Zacks Investment Research upgraded Emergent Biosolutions from a sell rating to a hold rating in a research note on Thursday, February 28th. Wells Fargo & Co set a $68.00 price objective on Emergent Biosolutions and gave the company a hold rating in a research note on Friday, March 1st. TheStreet downgraded Emergent Biosolutions from a b+ rating to a c+ rating in a research note on Tuesday, March 12th. Finally, Chardan Capital set a $71.00 price objective on Emergent Biosolutions and gave the company a buy rating in a research note on Friday, February 22nd. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $70.43.

Shares of Emergent Biosolutions stock traded down $0.22 during trading hours on Friday, reaching $52.89. 300,127 shares of the stock traded hands, compared to its average volume of 501,850. The company has a market cap of $2.72 billion, a P/E ratio of 22.70, a P/E/G ratio of 0.83 and a beta of 1.33. The company has a quick ratio of 2.07, a current ratio of 3.10 and a debt-to-equity ratio of 0.78. Emergent Biosolutions has a one year low of $46.93 and a one year high of $73.89.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, February 21st. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.14. The company had revenue of $270.70 million during the quarter, compared to the consensus estimate of $269.05 million. Emergent Biosolutions had a return on equity of 12.61% and a net margin of 8.02%. The firm’s revenue was up 39.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.74 EPS. Research analysts anticipate that Emergent Biosolutions will post 3.23 EPS for the current fiscal year.

In other Emergent Biosolutions news, CEO Daniel Abdun-Nabi sold 14,565 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $58.11, for a total value of $846,372.15. Following the completion of the transaction, the chief executive officer now directly owns 142,617 shares in the company, valued at approximately $8,287,473.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Adam Havey sold 2,430 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $56.93, for a total value of $138,339.90. Following the completion of the transaction, the executive vice president now owns 32,240 shares of the company’s stock, valued at $1,835,423.20. The disclosure for this sale can be found here. Insiders sold a total of 58,132 shares of company stock valued at $3,411,113 over the last 90 days. 13.40% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its holdings in shares of Emergent Biosolutions by 3.3% during the 4th quarter. BlackRock Inc. now owns 6,560,237 shares of the biopharmaceutical company’s stock worth $388,890,000 after acquiring an additional 209,332 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Emergent Biosolutions by 6.7% during the 3rd quarter. Vanguard Group Inc. now owns 4,603,209 shares of the biopharmaceutical company’s stock worth $303,029,000 after acquiring an additional 288,252 shares in the last quarter. Vanguard Group Inc raised its holdings in shares of Emergent Biosolutions by 6.7% during the 3rd quarter. Vanguard Group Inc now owns 4,603,209 shares of the biopharmaceutical company’s stock worth $303,029,000 after acquiring an additional 288,252 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Emergent Biosolutions by 12.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 851,840 shares of the biopharmaceutical company’s stock worth $56,077,000 after acquiring an additional 95,892 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Emergent Biosolutions during the 4th quarter worth approximately $49,581,000. Institutional investors and hedge funds own 84.63% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Further Reading: How are institutional investors different from individual investors?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.